716361-91-0

Usage

Uses

Used in Pharmaceutical Industry:
1-Methyl-1H-1,2,3-triazole-5-carboxylic acid is used as a reactant for the preparation of benzimidazolylazabicyclooctylethylpiperidine Ccr5 antagonists. These antagonists are crucial in the treatment of bacterial and viral infections, as well as other diseases. 1-Methyl-1H-1,2,3-triazole-5-carboxylic acid's unique structure allows it to interact with specific biological targets, making it a valuable component in the development of new therapeutic agents.

InChI:InChI=1/C4H5N3O2/c1-7-3(4(8)9)2-5-6-7/h2H,1H3,(H,8,9)

Upstream product

• 137156-35-5 3⁽¹⁾-methyl-3H(1H)-1,2,3-triazole-4⁽⁵⁾-carboxylate d'ethyle 
• 16681-65-5 1-methyl-1,2,3-triazole 
• 124-38-9 carbon dioxide 
• 202931-88-2 1-methyl-1H-1,2,3-triazole-5-carbaldehyde 

Downstream Products

• 1079402-46-2 C₄H₄ClN₃O 

Relevant academic research and scientific papers

METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain

Voltage-gated sodium channels, in particular Nav1.8, can be targeted for the treatment of neuropathic and inflammatory pain. Herein, we described the optimization of Nav1.8 modulator series to deliver subtype selective, state, and use-dependent chemical matter that is efficacious in preclinical models of neuropathic and inflammatory pain. (Chemical Presented).

FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF

The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

PYRIDINE DERIVATIVES

The present invention relates to compounds of the formula (I): (I) and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.